Message #14 From:
NewsBot Date: January 4, 2007 06:23:00 AM
GLIF News Grant Life Sciences Receives Cash Infusion
LOS ANGELES--(BUSINESS WIRE)--Grant Life Sciences (‘Grant’)
Inc. (OTC BB: GLIF) announced today that it has received a cash infusion
of $400,000. The company intends to use this cash to fill outstanding
orders for its products and continue validating its in-licensed
diagnostic opportunities.
“Taking in a relatively small amount of money—$400,000—at
this time provides us with a short-term connection to what management
hopes will be a much larger opportunity,”
said Hun-Chi Lin, Ph.D., Grant’s President
and Chief Scientist. “Indeed, we believe our
eagerness to announce this ‘small’
event should give our investors a sense of confidence about the
longer-term prospects for Grant Life Sciences, given the recent
announcements which demonstrate that we are executing our new corporate
strategy to: (1) acquire new products and technologies via in-licensing
activities; (2) out-license products for further development and sales;
and (3) drive sales through our established marketing channels. We
believe that this funding event underscores management’s
bullishness about Grant’s prospects in this
new year.”
About Grant Life Sciences Inc.
Grant Life Sciences engages in research, development, marketing, and
sale of diagnostic kits for the screening, monitoring, and diagnosis of
diseases with emphasis on women’s health,
infectious diseases, and cancers.
Forward-Looking Safe Harbor Statement
With the exception of historical information, the matters discussed in
this press release are "forward-looking statements" that involve a
number of risks and uncertainties. The actual future results of Grant
Life Sciences could differ significantly from those statements. Factors
that could cause actual results to differ materially include risks and
uncertainties such as the inability to finance the company's operations
or expansion, inability to hire and retain qualified personnel, changes
in the general economic climate, including rising interest rates and
unanticipated events such as terrorist activities, results of clinical
trials, and market acceptance of the Company's products. In some cases,
"forward-looking statements" can be identified by terminology such as
"may," "will," "should," "expect," "plan," "anticipate," "believe,"
"estimate," "predict," "potential" or "continue," or other comparable
terminology. Although Grant Life Sciences believes that the expectations
reflected in the "forward-looking" statements are reasonable, such
statements should not be regarded as a representation by the Company, or
any other person, that such "forward-looking statements" will be
achieved. Grant Life Sciences undertakes no duty to update any of the
"forward-looking statements," whether as a result of new information,
future events or otherwise. In light of the foregoing, readers are
cautioned not to place undue reliance on such "forward-looking
statements." For further risk factors associated with our Company,
review our SEC filings.
